George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 228.50
Bid: 228.50
Ask: 231.00
Change: 8.50 (3.86%)
Spread: 2.50 (1.094%)
Open: 222.00
High: 234.00
Low: 221.00
Prev. Close: 220.00
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

25 Jan 2017 09:02

RNS Number : 0652V
Oxford Biomedica PLC
25 January 2017
 

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons

 

1

Issuer

Oxford BioMedica PLC

2

Reason for notification

Notification relates to DTR 3.1.2R

3

Name of PDMR

Martin Diggle

4

Connected person

Notification relates to following connected persons:

Vulpes Life Sciences Fund

5

Notification in respect of

Notification in respect of holdings of persons in 4 above

6

Description of shares

Oxford BioMedica PLC ordinary shares of 1p each

7

Name of registered shareholders and number of shares

Vulpes Life Sciences Fund - 549,732,000 shares

Vulpes Testudo Fund - 33,333,333 shares

 

8

Nature of transaction

Acquisition

9

Number of shares acquired

 

Vulpes Life Sciences Fund - 200,000 shares

 

 

10

Percentage of issued class acquired

Vulpes Life Sciences Fund - 0.01%

 

11

Shares disposed

N/A

 

12

Percentage of issued class disposed

N/A

 

13/14

Price per share of transactions, and date

Vulpes Life Sciences Fund

200,000 shares @ £0.042 , 24 Jan 2017

 

15

Total holding following notification and total percentage holding following notification

Vulpes Life Sciences Fund - 549,932,000 shares

17.81%

Vulpes Testudo Fund - 33,333,333 shares

1.08%

16

Date issuer informed

25 Jan 2017

23

Any additional information

None

24

Contact name and telephone number

T. Watts, Chief Financial Officer

Oxford BioMedica

+44 (0)1865 783000

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHGCGDBBGDBGRU
Date   Source Headline
26th Apr 20237:00 amRNSBoard Appointment
25th Apr 20237:00 amRNSPreliminary results for the year ended 31 Dec 2022
19th Apr 20236:26 pmRNS2022 Preliminary results revised date
3rd Apr 20231:19 pmRNSTotal Voting Rights
30th Mar 20237:00 amRNSNotice of Preliminary Results
13th Mar 202311:33 amRNSOXB confirms no exposure to SVB receivership
1st Mar 202311:16 amRNSTotal Voting Rights
20th Feb 20237:00 amRNSDr Frank Mathias to join as new CEO on 27 March
1st Feb 202310:18 amRNSTotal Voting Rights
27th Jan 20237:00 amRNSBoard Change
3rd Jan 20235:19 pmRNSBlock listing return
3rd Jan 202311:28 amRNSTotal Voting Rights
21st Dec 202212:00 pmRNSOxford Biomedica to Present at J.P Morgan
14th Dec 20227:00 amRNSOxford Biomedica Solutions forms new partnerships
22nd Nov 20227:00 amRNSOxford Biomedica Appoints Frank Mathias as CEO
15th Nov 20222:35 pmRNSHolding(s) in Company
14th Nov 20227:00 amRNSSale and leaseback of Windrush Court facility
1st Nov 20229:14 amRNSTotal Voting Rights
14th Oct 20222:28 pmRNSPDMR Dealings
12th Oct 20227:00 amRNSPDMR Dealings
12th Oct 20227:00 amRNSPDMR Dealings
7th Oct 20221:16 pmRNSPDMR Dealing Amendment
7th Oct 202212:28 pmRNSPDMR Dealing
7th Oct 20227:00 amRNSAmendment of Short-Term Loan Facility
3rd Oct 20229:34 amRNSTotal Voting Rights
15th Sep 20227:00 amRNSInterim Results
14th Sep 20227:00 amRNSOxford Biomedica Solutions signs new partner
7th Sep 20227:00 amRNSLicence & Supply Agreement with New Partner
1st Sep 20229:51 amRNSTotal Voting Rights
25th Aug 20227:00 amRNSNotice of Interim Results
16th Aug 20227:00 amRNSOxford Biomedica Notes Homology Q2 Report
1st Aug 20229:42 amRNSTotal Voting Rights
27th Jul 20227:00 amRNSAppointment of Joint Corporate Broker
26th Jul 20227:00 amRNSLicence & Supply Agreement with New Partner
26th Jul 20227:00 amRNSNew Project with Orchard Therapeutics
21st Jul 20227:00 amRNSExpanded Agreement with BMS’s Juno in CAR-T
15th Jul 202210:13 amRNSBLOCK LISTING RETURN
1st Jul 20229:55 amRNSTotal Voting Rights
1st Jul 20227:00 amRNSSigns new agreement with AstraZeneca
14th Jun 20227:00 amRNSNotes FDA lift clinical hold on pheNIX trial
1st Jun 20227:00 amRNSTotal Voting Rights
27th May 20226:03 pmRNSResult of AGM
3rd May 20225:18 pmRNSGrant of options
3rd May 20224:46 pmRNSDirector/PDMR Shareholding
3rd May 202210:35 amRNSTotal Voting Rights
29th Apr 20225:42 pmRNSDirectors Dealings / Market Share Purchases
28th Apr 20222:24 pmRNSDirector/PDMR Shareholding
27th Apr 20222:58 pmRNS2021 Annual report and accounts & AGM notification
27th Apr 202212:10 pmRNSPDMR Dealings / Market Share Purchase
21st Apr 20224:41 pmRNSDirector Share Purchase

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.